» Articles » PMID: 34694719

Biosynthesis and Characterisation of Solid Lipid Nanoparticles and Investigation of Toxicity Against Breast Cancer Cell Line

Overview
Publisher Wiley
Specialty Biotechnology
Date 2021 Oct 25
PMID 34694719
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Solid lipid nanoparticles (SLNs) comprise non-toxic surface-active lipidic agents combined with appropriate ratios of drugs or essential oils. The goal of this research was to investigate the effects of the SLN synthesised using essential oils of Foeniculum vulgare on the MCF-7 breast cancer cell line. SLNs were prepared by homogenisation and ultrasound techniques and characterised by dynamic light scattering (DLS), zeta potential assessment, and transmission electron microscopy (TEM). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay (MTT assay), flow-cytometry, and Acridine-Orange assay were employed for assessing the biological activities of the SLNs. The average particle size was 55.43 nm and the net surface charge was -29.54 ± 11.67 mV. TEM showed that the mean particle size was 33.55 nm and the synthesised SLNs had a uniform round morphology. The MTT assay showed that the prepared SLNs had high toxicity against MCF-7 cells and low toxicity against normal HUVECs cells. Flow-cytometry revealed a noteworthy rise in the subG1 peak of the cell cycle in the cancer cells treated with SLNs compared to the controls, indicating apoptosis in cancer cells. The results also showed discolouration in SLNs-treated cells, which further confirmed the induction of apoptosis and the toxicity of the SLNs against MCF-7 cells.

Citing Articles

A quality-by-design approach to develop abemaciclib solid lipid nanoparticles for targeting breast cancer cell lines.

Chin B, Meng Lim W, Almurisi S, Madheswaran T Ther Deliv. 2025; 16(2):123-137.

PMID: 39878544 PMC: 11849948. DOI: 10.1080/20415990.2025.2457314.


Beyond aromatherapy: can essential oil loaded nanocarriers revolutionize cancer treatment?.

Alabrahim O, Lababidi J, Fritzsche W, Azzazy H Nanoscale Adv. 2024; .

PMID: 39415775 PMC: 11474398. DOI: 10.1039/d4na00678j.


Effects of solid lipid nanocarrier containing methyl urolithin A by coating folate-bound chitosan and evaluation of its anti-cancer activity.

Al-Fatlawi I, Pouresmaeil V, Davoodi-Dehaghani F, Pouresmaeil A, Akhtari A, Homayouni Tabrizi M BMC Biotechnol. 2024; 24(1):18.

PMID: 38600497 PMC: 11005287. DOI: 10.1186/s12896-024-00845-6.


Anticancer Applications of Essential Oils Formulated into Lipid-Based Delivery Nanosystems.

Jampilek J, Kralova K Pharmaceutics. 2022; 14(12).

PMID: 36559176 PMC: 9781429. DOI: 10.3390/pharmaceutics14122681.


Review targeted drug delivery systems for norcantharidin in cancer therapy.

Zhai B, Sun J, Shi Y, Zhang X, Zou J, Cheng J J Nanobiotechnology. 2022; 20(1):509.

PMID: 36463199 PMC: 9719664. DOI: 10.1186/s12951-022-01703-3.


References
1.
Zarei M, Karimi E, Oskoueian E, Es-Haghi A, Taghavizadeh Yazdi M . Comparative Study on the Biological Effects of Sodium Citrate-Based and Apigenin-Based Synthesized Silver Nanoparticles. Nutr Cancer. 2020; 73(8):1511-1519. DOI: 10.1080/01635581.2020.1801780. View

2.
El-Garawani I, El-Sabbagh S, Abbas N, Ahmed H, Eissa O, Abo-Atya D . A newly isolated strain of Halomonas sp. (HA1) exerts anticancer potential via induction of apoptosis and G/M arrest in hepatocellular carcinoma (HepG2) cell line. Sci Rep. 2020; 10(1):14076. PMC: 7443142. DOI: 10.1038/s41598-020-70945-8. View

3.
Kang K, Chun M, Kim O, Subedi R, Ahn S, Yoon J . Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine. 2010; 6(2):210-3. DOI: 10.1016/j.nano.2009.12.006. View

4.
Satpathy G, Chandra G, Manikandan E, Mahapatra D, Umapathy S . Pathogenic Escherichia coli (E. coli) detection through tuned nanoparticles enhancement study. Biotechnol Lett. 2020; 42(5):853-863. DOI: 10.1007/s10529-020-02835-y. View

5.
Wissing S, Kayser O, Muller R . Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004; 56(9):1257-72. DOI: 10.1016/j.addr.2003.12.002. View